Shares of Tilray Inc (NASDAQ:TLRY - Get Free Report) were up 2.2% on Friday . The stock traded as high as $1.18 and last traded at $1.15. Approximately 12,110,177 shares were traded during trading, a decline of 71% from the average daily volume of 42,268,156 shares. The stock had previously closed at $1.12.
Analysts Set New Price Targets
TLRY has been the subject of a number of analyst reports. Roth Mkm dropped their price objective on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating for the company in a report on Friday, October 11th. Canaccord Genuity Group increased their price target on shares of Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research note on Monday, January 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $2.70.
Read Our Latest Research Report on TLRY
Tilray Stock Up 1.8 %
The business has a 50-day moving average of $1.30 and a 200-day moving average of $1.58. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.80 and a beta of 2.08.
Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.07). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $210.90 million during the quarter, compared to analysts' expectations of $216.34 million. Tilray's revenue for the quarter was up 8.7% on a year-over-year basis. On average, sell-side analysts expect that Tilray Inc will post -0.2 EPS for the current year.
Insiders Place Their Bets
In other Tilray news, CFO Carl A. Merton acquired 26,000 shares of the stock in a transaction dated Friday, November 15th. The stock was acquired at an average price of $1.36 per share, with a total value of $35,360.00. Following the completion of the purchase, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.87% of the stock is owned by insiders.
Institutional Investors Weigh In On Tilray
A number of hedge funds have recently added to or reduced their stakes in TLRY. Bank of Montreal Can grew its position in shares of Tilray by 0.3% during the third quarter. Bank of Montreal Can now owns 2,176,506 shares of the company's stock worth $3,787,000 after buying an additional 7,406 shares in the last quarter. State Street Corp lifted its stake in Tilray by 4.7% in the third quarter. State Street Corp now owns 1,961,338 shares of the company's stock worth $3,452,000 after acquiring an additional 88,079 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Tilray by 1,314.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock worth $3,202,000 after acquiring an additional 1,690,827 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Tilray by 6.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company's stock valued at $2,953,000 after purchasing an additional 107,530 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Tilray by 2.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,487,500 shares of the company's stock valued at $2,617,000 after purchasing an additional 37,300 shares during the last quarter. 9.35% of the stock is currently owned by institutional investors and hedge funds.
Tilray Company Profile
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Read More
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
